Imara
Cambridge
About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $144.8M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jul 2021)
- Ticker: nasdaq:IMRA
- Website: imaratx.com
- Phone: 617 231-6021
Industries & Categories
Biopharma, Biotechnology, Genetics, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/imara-174593 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.